Kyoto, Japan-based Kyocera (TYO:6971) said it will buy the major assets of Renovis Surgical Technologies’ artificial joint and spinal products businesses to expand its U.S. footprint.
Kyocera will transfer the assets into a new, wholly owned, California-based company to be named Kyocera Medical Technologies in March 2019. Kyocera manufactures medical products, including artificial joints and dental implants, primarily for the Japanese market. The company obtained 510(k) clearance for its artificial hip joints in 2017 and began selling them in the U.S. the following year.
Founded in 2009, Renovis (Redlands, Calif.) designs and manufactures implants for the orthopedic and neurological markets and for trauma surgery. The company won 510(k) clearance for its Tesera X Lateral Interbody Fusion System in 2018. Tesera X uses the company’s 3D-printed porous architecture that is made using additively manufactured titanium alloy. Renovis has also developed an advanced bearing surface technology for joint replacement products.
The new company will use Kyocera’s proprietary technologies and those purchased from Renovis to develop new products, according to Kyocera, which also manufactures semiconductor packages, industrial and automotive components, electronic devices, solar power generating systems, printers, copiers and mobile phones. During the year ended March 31, 2018, Kyocera’s consolidated net sales totaled 1.58 trillion yen (approximately $14.9 billion).
